Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)

  1. Peeters, M.
  2. Price, T.
  3. Hotko, Y.
  4. Cervantes, A.
  5. Ducreux, M.
  6. Andre, T.
  7. Chan, E.
  8. Lordick, F.
  9. Rong, A.
  10. Gansert, J.
Journal:
EJC SUPPLEMENTS

ISSN: 1359-6349,  1878-1217

Year of publication: 2009

Volume: 7

Issue: 3

Pages: 10-10

Congress: 15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology

Type: Conference paper

DOI: 10.1016/S1359-6349(09)72049-X GOOGLE SCHOLAR
Data source: WoS